Subject: Specialty Quantity Limit Rasuvo 2273-H P2023

Drug

RASUVO  (methotrexate injection)

Policy:

      I.  PROGRAM DESCRIPTION

          The standard limit is designed to allow a quantity sufficient for
          the most common uses of the medication. The recommended
          dosing parameters for all FDA-approved indications fall within
          the standard limits. Coverage of an additional quantity may be
          reviewed on a case-by-case basis upon request.  

 
    II.  COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Rasuvo (methotrexate   injection)   -  7.5 mg per 0.15 ml   -  10 mg per 0.2 ml   -  12.5 mg per 0.25 ml   -  15 mg per 0.3 ml   -  17.5 mg per 0.35 ml   -  20 mg per 0.4 ml   -  22.5 mg per 0.45 ml   -  25 mg per 0.5 ml   -  30 mg per 0.6 ml   single-dose auto-injector   for subcutaneous injection	4 injections per 28 days	Rheumatoid arthritis   •  7.5 mg every week (adjust      gradually to achieve an      optimal response); up to 20      mg per week   Polyarticular juvenile   idiopathic arthritis   •  10 mg per m2 every week      (adjust gradually to achieve      an optimal response); up to      20 mg per m2 per week   Psoriasis   •  10 to 25 mg every week      (adjust gradually to achieve      an optimal response); up to      30 mg per week

 

 

Place of Service:

Outpatient

The above policy is based on the following references:

1. Rasuvo [package insert]. Chicago, IL: Medexus Pharma Inc.; March 2020.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

April 11, 2023